{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:32:37Z","timestamp":1789774357427,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.atherosclerosis.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T11:15:22Z","timestamp":1596021322000},"page":"6-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies"],"prefix":"10.1016","volume":"308","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1791-4506","authenticated-orcid":false,"given":"Andrea","family":"Pasta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-2371","authenticated-orcid":false,"given":"Anna Laura","family":"Cremonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-4566","authenticated-orcid":false,"given":"Elena","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Fresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Pisciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib1","first-page":"169","article-title":"Familial hypercholesterolemia","volume":"33","author":"Bouhairie","year":"2015","journal-title":"Cardiol. Clin."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","article-title":"Familial hypercholesterolemia--epidemiology, diagnosis, and screening","volume":"17","author":"Singh","year":"2015","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib3","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib4","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"National lipid association expert panel on familial hypercholesterolemia, familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the national lipid association expert panel on familial hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib6","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1161\/01.ATV.20.9.e41","article-title":"Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype","volume":"20","author":"Bertolini","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2013.01.007","article-title":"Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy","volume":"227","author":"Bertolini","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2017.07.003","article-title":"The study of familial hypercholesterolemia in Italy: a narrative review","volume":"29","author":"Bertolini","year":"2017","journal-title":"Atherosclerosis Suppl."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosissup.2017.07.001","article-title":"LIPIGEN group, familial hypercholesterolemia: the Italian atherosclerosis society network (LIPIGEN)","volume":"29","author":"Averna","year":"2017","journal-title":"Atherosclerosis Suppl."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.ATV.19.2.408","article-title":"Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia","volume":"19","author":"Bertolini","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061676","article-title":"Validation of LDLr activity as a tool to improve genetic diagnosis of familial hypercholesterolemia: a retrospective on functional characterization of LDLr variants","volume":"19","author":"Benito-Vicente","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","article-title":"Familial hypercholesterolemia treatments: guidelines and new therapies","volume":"277","author":"Raal","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib15","author":"Repatha"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib16","author":"Praluent"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib17","author":"Gazzetta Ufficiale"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib18","author":"Gazzetta Ufficiale"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib19","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2012.10.032","article-title":"Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?","volume":"226","author":"Vuorio","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jcmg.2013.11.014","article-title":"Carotid intima-media thickness and plaque in cardiovascular risk assessment","volume":"7","author":"Naqvi","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib23","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/00004872-200406000-00022","article-title":"ELSA Investigators, Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA)","volume":"22","author":"Zanchetti","year":"2004","journal-title":"J. Hypertens."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jpeds.2009.02.022","article-title":"The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia","volume":"155","author":"Guardamagna","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2012.12.016","article-title":"The effect of LDLR-negative genotype on CT coronary atherosclerosis in asymptomatic statin treated patients with heterozygous familial hypercholesterolemia","volume":"227","author":"Ten Kate","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2013.12.028","article-title":"Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia","volume":"233","author":"Santos","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h1551","article-title":"Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium","volume":"350","author":"Mons","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2011.03.027","article-title":"Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades","volume":"108","author":"Elis","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1586\/erc.13.7","article-title":"Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes","volume":"11","author":"Alonso","year":"2013","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib31","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib32","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/S2468-2667(19)30189-6","article-title":"Italy's health performance, 1990-2017: findings from the Global Burden of Disease Study 2017","volume":"4","author":"Gbd 2017 Italy Collaborators","year":"2019","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz746.0332","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","author":"Guedeney","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.atherosclerosis.2019.02.003","article-title":"Dyslipidemia Registry of Spanish Atherosclerosis Society. Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia","volume":"284","author":"Perez-Calahorra","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jacl.2019.10.005","article-title":"Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: the SAFEHEART study","volume":"13","author":"P\u00e9rez de Isla","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib36","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1073\/pnas.86.11.4171","article-title":"Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis","volume":"86","author":"Utermann","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib37","unstructured":"S. Bertolini, P. Masturzo, G. Pistocchi, N. Elicio, R. Balestreri. Lp(a) levels in patients with Familial Hypercholesterolemia (FH) and in their offspring. Second Internat. Conference on Lipoprotein(a) (New Orleans, November 12-14, 1992). Abs. Book p. 157."},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40265-019-01243-5","article-title":"Potential of lipoprotein(a)-lowering strategies in treating coronary artery disease","volume":"80","author":"Gencer","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib39","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jacl.2019.06.011","article-title":"Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels","volume":"13","author":"Pavanello","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2020.07.006_bib40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/joim.12981","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities","volume":"287","author":"Vuorio","year":"2020","journal-title":"J. Intern. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020303671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020303671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:25:03Z","timestamp":1762187103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020303671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":40,"alternative-id":["S0021915020303671"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.07.006","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}